| Collaboration revenue | — | — | — |
| Collaboration revenue from customers | | 330.53a | 105.07a |
| Other collaboration revenue | | | 3.4a |
| Total collaboration revenue | | 330.53a | 108.46a |
| Operating expenses | — | — | — |
| Research and development | -396.44a | -423.88a | -358.73a |
| General and administrative | -105.44a | -103.35a | -90.48a |
| Total operating expenses | -501.88a | -527.23a | -449.21a |
| Gain from divestiture of small molecule programs | 14.54a | | |
| Loss from operations | -487.34a | -196.7a | -340.74a |
| Interest and other income, net | 64.64a | 51.51a | 14.77a |
| Loss before income taxes | -422.71a | -145.19a | -325.97a |
| Income tax expense | -0.07a | -0.03a | -0.02a |
| Net loss | -422.77a | -145.22a | -325.99a |